bm|t beteiligungsmanagement thüringen gmbh invests in Dentognostics GmbH.
bm|t has acquired a 28% stake in the Jena-based company as a first step as part of a capital increase. For bm|t, this is its tenth investment undertaking in the area of life sciences / biotechnology. Apart from bm|t, a number of private investors and tbg Technologiebeteiligungsgesellschaft mbH have also invested in the company. A total of €2.2 million have been invested in Dentognostics.
Expansion of research and development activities
Dentognostics GmbH is using the fresh money to develop its products – rapid tests to support the treatment and prevention of dental diseases. These include tests to evaluate the risk of caries and tests to monitor the treatment of severe parodontitis or to discover the cause of chronic halitosis.
Dentognostics’ rapid tests will be tested from the middle of next year in dental surgeries. The rapid tests can be carried out during treatment. Both patient and dentist will get the results immediately and the necessary treatment or preventive measures can be taken early on and targeted appropriately.